Loading…
Lixte Biotechnology Holdings, Inc. is projected to rise to $8.50 by 2027, a +18% move from its current price of $7.21. LIXT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.75 | $7.22 | $7.72 | +0.14% |
| Jul 14 | $6.58 | $7.23 | $7.95 | +0.28% |
| Jul 15 | $6.45 | $7.24 | $8.13 | +0.41% |
| Jul 16 | $6.34 | $7.25 | $8.29 | +0.55% |
| Jul 17 | $6.25 | $7.26 | $8.43 | +0.69% |
| Jul 18 | $6.17 | $7.27 | $8.57 | +0.83% |
| Jul 19 | $6.10 | $7.28 | $8.69 | +0.97% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.10 | $7.28 | $8.69 | +0.97% |
| Week 2 | $5.72 | $7.35 | $9.45 | +1.94% |
| Week 3 | $5.46 | $7.42 | $10.09 | +2.93% |
| Week 4 | $5.25 | $7.49 | $10.69 | +3.93% |
| Week 5 | $5.09 | $7.57 | $11.25 | +4.93% |
| Week 6 | $4.95 | $7.64 | $11.80 | +5.95% |
| Week 7 | $4.82 | $7.71 | $12.34 | +6.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company that focuses on identifying targets for cancer drug development and on developing and commercializing cancer therapies.
Its lead product candidate, LB-100, is in phase 1b clinical trials combined with Atezolizumab for microsatellite stable metastatic colorectal cancer. LB-100 combined with doxorubicin in advanced soft tissue sarcoma is in Phase 1b, and LB-100 with dostarlimab is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute, a collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
Lixte Biotechnology Holdings, Inc. trades in the healthcare space under the ticker LIXT. The current price is $7.21 and the stock sits with a market cap of $125.36M, ranking 3995.
The technical picture presents a bullish flavor, with a sentiment labeled BULLISH and a 30-day trading range that reflects meaningful activity between $4.97 and $10.46.
Key indicators show RSI(14) at 50, SMA(50) at $5.83, and SMA(200) at $4.31, alongside a stated support of $5.60 and resistance of $8.04. Annualized volatility is high at 100%, underscoring notable price swings.
A major floor 66.2% below — a decisive break under it would weaken the trend.
The nearest floor, 16.9% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 22.2% above — clearing it would confirm fresh momentum.
Key LIXT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIXT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.58 | Buy | $6.57 | Buy |
| MA 10 | $7.04 | Buy | $6.80 | Buy |
| MA 20 | $7.02 | Buy | $6.83 | Buy |
| MA 50 | $6.11 | Buy | $6.13 | Buy |
| MA 100 | $4.58 | Buy | $5.26 | Buy |
| MA 200 | $4.34 | Buy | $4.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.10 | Neutral |
| Stoch RSI (14) | 9.81 | Buy |
| CCI (20) | -116.49 | Sell |
| Williams %R (14) | -91.75 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -14.25 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 8.25 | Buy |
| TRIX (15) | 0.71 | Buy |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 37.80 | Neutral |
| Momentum (10) | -0.39 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 6.16 | Buy |
| ADX (14) | 18.81 | Neutral |
| ATR (14) | 0.44 | Info |
In the near term, the chart shows a bullish tilt with the stock oscillating within a roughly $4.97 to $10.46 30-day range. RSI(14) sits at 50, which is neutral, while the SMA50 of $5.83 sits above the current price of $7.21 and the SMA200 of $4.31.
Support is identified at $5.60 and resistance at $8.04, framing a constructive but cautious short-term setup given the 30-day volatility. Overall, the technical picture points to ongoing momentum without a clear overbought signal in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.44 | $7.21 | $11.16 | 0% | Neutral | |
| $6.17 | $8.50 | $12.67 | +18% | Neutral | |
| $6.15 | $9.01 | $14.31 | +25% | Bullish | |
| $7.23 | $11.16 | $18.60 | +55% | Bullish | |
| $8.61 | $13.92 | $24.17 | +93% | Bullish | |
| $11.63 | $19.66 | $35.32 | +173% | Bullish | |
| $12.93 | $22.80 | $42.23 | +216% | Bullish | |
| $13.28 | $24.38 | $46.42 | +238% | Bullish | |
| $12.78 | $24.40 | $47.64 | +238% | Bullish | |
| $11.37 | $22.58 | $45.10 | +213% | Bullish | |
| $19.61 | $43.58 | $95.66 | +504% | Bullish | |
| $60.69 | $134.87 | $310.19 | +17.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.44 | $7.21 | $8.78 | +0.00% |
| August 2026 | $6.17 | $7.47 | $9.42 | +3.57% |
| September 2026 | $6.65 | $8.17 | $10.53 | +9.46% |
| October 2026 | $6.73 | $8.36 | $10.96 | +2.33% |
| November 2026 | $6.45 | $8.10 | $10.77 | -3.17% |
| December 2026 | $6.53 | $8.28 | $11.16 | +2.26% |
Click any year to see its month-by-month LIXT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The LIXT price prediction for 2026 points to an average of $7.21 (low $2.44, high $11.16) — a potential gain of 0% on today's $7.21. Price action looks broadly range-bound.
In 2027, LIXT is projected to trade between $6.17 and $12.67, averaging $8.50 — a potential gain of +18% from today's $7.21. That is up +18% on the projected 2026 average. A consolidation phase looks the most probable path here.
Lixte Biotechnology Holdings, Inc.'s 2028 outlook centres on $9.01, within a $6.15 to $14.31 range. That is up +6% on the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, LIXT could reach as high as $18.60, with a base case around $11.16 and support toward $7.23 — roughly +55% from $7.21. Buyers look set to stay in control over this stretch.
Expect LIXT to range from $8.61 to $24.17 through 2030. The $13.92 average target implies a +93% move from current prices. That is up +25% on the projected 2029 average. Momentum favours further upside here.
The LIXT price prediction for 2031 points to an average of $19.66 (low $11.63, high $35.32) — a potential gain of +173% on today's $7.21. Buyers look set to stay in control over this stretch.
In 2032, LIXT is projected to trade between $12.93 and $42.23, averaging $22.80 — a potential gain of +216% from today's $7.21. That is up +16% on the projected 2031 average. Momentum favours further upside here.
Lixte Biotechnology Holdings, Inc.'s 2033 outlook centres on $24.38, within a $13.28 to $46.42 range. That is up +7% on the projected 2032 average. That marks a +238% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, LIXT could reach as high as $47.64, with a base case around $24.40 and support toward $12.78 — roughly +238% from $7.21. Momentum favours further upside here.
Expect LIXT to range from $11.37 to $45.10 through 2035. The $22.58 average target implies a +213% move from current prices. That is -7% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The LIXT price prediction for 2040 points to an average of $43.58 (low $19.61, high $95.66) — a potential gain of +504% on today's $7.21. Momentum favours further upside here.
In 2050, LIXT is projected to trade between $60.69 and $310.19, averaging $134.87 — a potential gain of +17.7x from today's $7.21. That is up +209% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LIXT today (≈ 138.696255 LIXT) could be worth
$18,705.3
+$17,705.3 (+1771%) by 2050 · US Dollar
Based on the average projected LIXT price of $134.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIXTwould be worth at today's price.
$1,000 invested in LIXT on Jul 10, 2025 (≈ 236.966836 LIXT) would be worth
$1,708.53
+$708.53 (+70.9%) today · 1.71× · US Dollar
Based on a LIXT entry price of $4.22 vs. today's $7.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.21 | $1,000 | -0.0% |
| 1 month ago | $6.89 | $1,046.44 | +4.6% |
| 3 months ago | $3.05 | $2,363.93 | +136.4% |
| 6 months ago | $3.4 | $2,120.59 | +112.1% |
| 1 year ago | $4.22 | $1,708.53 | +70.9% |
| All time (5.0y) ago | $31.8 | $226.73 | -77.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIXT forecast.
Our base-case forecast reaches $14.00 around 2031.
Implied market cap at $14.00: $243.41M
The multi-year forecast shows a path of rising averages and strong upside potential, albeit as estimates rather than guarantees. For 2026 the avg price is $7.21 with a min of $2.44 and a max of $11.29, and a neutral sentiment alongside a 0% ROI. By 2027 the avg is $8.35 with a 15.8% ROI and neutral sentiment, followed by a bullish shift through 2028 (avg $8.85, ROI 22.8%).
The forecast accelerates significantly in later years, with 2029 at an avg of $11.53 (ROI 60%), 2030 at $14.26 (ROI 97.8%), and 2031 at $19.71 (ROI 173.4%). By 2040 the avg price is projected to $43.31 with a 500.7% ROI, and by 2050 the avg price reaches $134.29 with a 1,762.6% ROI, continuing the bullish outlook. Drivers and risks include clinical progression, regulatory milestones, and market dynamics, but these are estimates and not guarantees.
Overall, the longer-term path shows substantial upside, tempered by the inherent uncertainty and volatility of clinical-stage biotechnology. The forecasts illustrate meaningful upside potential but should be interpreted in the context of risks that can affect medical development timelines and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $14.26 with a max of $24.77 and a min of $8.81, along with a 97.8% ROI and bullish sentiment.
Forecasts project a bullish trend from 2027 onward with rising average prices (e.g., $8.35 in 2027, $14.26 in 2030) and positive ROIs (e.g., 97.8% by 2030 and higher thereafter), but 2026 is neutral with a 0% ROI. These are estimates, not guarantees.
Yes, the 2050 forecast shows a min of $60.43, an average of $134.29, and a max of $308.87 with a 1,762.6% ROI and bullish sentiment, recognizing this is a forecast and not a guarantee.
Current price is $7.21 and market cap is $125.36M, with a rank of 3995.
The sentiment is bullish, RSI(14) is 50, SMA(50) is $5.83, SMA(200) is $4.31. The 30-day range is $4.97 to $10.46, with support at $5.60 and resistance at $8.04; annualized volatility is 100%.
Lixte Biotechnology Holdings, Inc. Community Discussion
0Share your Lixte Biotechnology Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.